<DOC>
	<DOCNO>NCT01539239</DOCNO>
	<brief_summary>This clinical trial prospective , randomize , control , multicenter , study . After informed consent obtain , patient evaluate eligibility base glaucoma severity , eye health , visual acuity . Following successful screening , use topical glaucoma medication stop period `` washout '' establish qualify medication-free intraocular pressure ( IOP ) value . Clinical follow schedule course 24 month study , examination repeat monitor eye health . At 1 2 year follow , patient ocular hypotensive medication instruct washout , diurnal ( IOP take morning , mid-day , afternoon day ) IOP evaluation . Annual follow occur 5 year . The primary effectiveness endpoint decrease diurnal IOP baseline compare 24 month diurnal IOP follow medication washout .</brief_summary>
	<brief_title>Safety &amp; Effectiveness Study Hydrus Device Lowering IOP Glaucoma Patients Undergoing Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>An operable agerelated cataract A diagnosis POAG treat 1 4 hypotensive medication Medicated IOP ≤ 31 mmHg Diurnal IOP ≥ 22 mmHg ≤ 34 mmHg Congenital developmental glaucoma Previous argon laser trabeculoplasty Abinterno abexterno device implant Schlemm 's Canal Use oral hypotensive medication glaucoma treatment fellow eye</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>POAG</keyword>
	<keyword>Cataract</keyword>
</DOC>